Open Letter to Zomedica Shareholders from your Chief Executive Officer
ANN ARBOR, MI / ACCESSWIRE / January 31, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
COVID-19
HCA Healthcare Reports Fourth Quarter 2023 Results and Provides 2024 Guidance
Bill Rutherford to Retire and Mike Marks to Become CFONASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and...
CorVel Announces Revenues and Earnings
FORT WORTH, Texas, Jan. 30, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended...
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong...
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
Science 37 stockholders to receive $5.75 per share in cashRESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science...
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared...
Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote “FOR” Proposed Reverse Stock Split
ANN ARBOR, MI / ACCESSWIRE / January 25, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but...
Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.
Webinar to be hosted on January 31, 2024 at 1:00 pm. ETCHATHAM, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tonix...
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
Interim Data Analysis Anticipated in Mid-2024Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics,...
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
Press Release Nicox Provides Fourth Quarter 2023 Financial and Business Highlights NCX 470 Phase 3 Denali clinical trial 75% randomizedNet...
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators
New appointments bring deep research and development expertise and technology innovation to support continued advancement of ReAlta’s EPICC Technology PlatformNORFOLK,...
Ainos Announces $1.75 Million Follow-On Funding
The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023.Use of...
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine...
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and...
STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024
DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it...